TDP-43 Proteinopathy Investment

Overview

This page summarizes trial-derived R&D investment signals for TDP-43 proteinopathy therapeutics, primarily focused on Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), the two conditions where TDP-43 pathology is most prominent. TDP-43 (TAR DNA-binding protein 43) aggregates are found in ~95% of ALS cases and ~50% of FTD cases [@neumann2006][@arai2006].

Portfolio Metrics

Metric	ALS	FTD
Total tracked trials	750	113
Active trials	189 (25.2%)	31 (27.4%)
Completed trials	351 (46.8%)	41 (36.3%)
Late-stage (Phase 3/4)	70 (9.3%)	6 (5.3%)
Phase 1/2 programs	275 (36.7%)	18 (15.9%)

Combined TDP-43 Pipeline: 863 trials across ALS and FTD

Therapeutic Approach Categories

Small Molecule Approaches

Approach	ALS Trials	FTD Trials	Status
Mitochondrial modulators	525	Limited	Most advanced
Genetic targeting	52	12	Growing
Neuroinflammation targets	10	8	Early stage
Neurotransmitter modulation	5	3	Established
Growth factor therapy	6	2	Early stage

Gene Therapy and Antibody Approaches

The TDP-43 proteinopathy field is increasingly focusing on:

Antisense oligonucleotides (ASOs): Targeting TARDBP gene expression
Gene replacement: Delivering functional TDP-43
Antibody therapies: Anti-TDP-43 monoclonal antibodies
Small molecules: Aggregation inhibitors, autophagy enhancers

Trial Status Distribution

ALS Trial Status

Category	Trial Count	Share
Active/Recruiting	189	25.2%
Recruiting	122	16.3%
Not Yet Recruiting	27	3.6%
Active Not Recruiting	34	4.5%
Enrolling By Invitation	6	0.8%
Historical	561	74.8%
Completed	351	46.8%
Terminated	66	8.8%
Withdrawn	28	3.7%
Unknown	100	13.3%

FTD Trial Status

Category	Trial Count	Share
Active/Recruiting	31	27.4%
Historical	82	72.6%
Completed	41	36.3%
Terminated	12	10.6%
Withdrawn	8	7.1%

Mechanism Cluster Distribution

flowchart TD
%%{init: {'theme': 'base', 'themeVariables': {'pie1': '#4a90d9', 'pie2': '#50c878', 'pie3': '#f5a623', 'pie4': '#d0021b', 'pie5': '#9013fe', 'pie6': '#b8e986'}}}%%

Mechanism Cluster	ALS Trials	Primary Focus
Mitochondrial biology	525 (70.0%)	Energy metabolism, oxidative stress
Genetic / gene-targeted	52 (6.9%)	SOD1, C9orf72, TARDBP
Amyloid biology	14 (1.9%)	TDP-43 aggregation
Neuroinflammation	10 (1.3%)	Microglial modulation
Synaptic function	7 (0.9%)	Neuroprotection
Growth factor	6 (0.8%)	Neuronal support

Key Insight: Mitochondrial dysfunction dominates the ALS pipeline (70%), reflecting the central role of energy failure in TDP-43 proteinopathy [@cozzolino2019].

Sponsor Landscape

Top Academic Sponsors (ALS)

Sponsor	Trial Count
Peking University Third Hospital	18
Assistance Publique - Hopitaux de Paris	17
Massachusetts General Hospital	13
University of Michigan	11
Drexel University College of Medicine	10
Mayo Clinic	9
Johns Hopkins University	8
University of Miami	8

Pharmaceutical Companies

Company	ALS Trials	Notable Programs
Biogen	8	ASO therapies, C9orf72
Cytokinetics	8	Tirasemtiv, reldesemtiv
Knopp Biosciences	9	KD7000 series
Amylyx Pharmaceuticals	5	AMX0035 (approved)
Neuralstem	4	Cell therapy
Roche	3	Genentech collaboration

Gap Analysis

Underexplored Areas

TDP-43 Aggregation Inhibitors: Few trials specifically targeting TDP-43 aggregation
FTD-Specific Programs: Only 113 trials vs 750 for ALS — significant imbalance
Biomarker-Driven Trials: Limited incorporation of TDP-43 biomarkers
Combination Therapies: Almost no combination approach trials
Prevention Trials: Few trials targeting pre-symptomatic carriers

Strategic Opportunities

TDP-43-Targeted ASOs: Direct targeting of TARDBP expression
C9orf72 Programs: Expansion of repeat expansion-targeted approaches
Autophagy Enhancement: Clearing TDP-43 aggregates
FTD Pipeline Development: Significant unmet need and opportunity
Biomarker Integration: TDP-43 in CSF/blood as stratification marker

TDP-43 Proteinopathy Investment Landscape